News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Dec 4, 2018

Summary Toggle aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)

FSR Clinical Studies Network to assist with clinical site initiation to expedite patient enrollment SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological
Nov 28, 2018

Summary Toggle aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference

SAN DIEGO , Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., president and chief executive officer,
Nov 13, 2018

Summary Toggle aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update

- Initiation of Proof-of-Concept Study in Patients with Pulmonary Sarcoidosis Planned for Fourth Quarter of 2018 - - Conference Call Today at 5:00 p.m. ET / 2:00 p.m. PT – SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
Nov 8, 2018

Summary Toggle aTyr Pharma to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 13, 2018

SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its third quarter financial results on Tuesday,
Oct 17, 2018

Summary Toggle aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting

SAN DIEGO , Oct. 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a presentation at the American Society of Human Genetics 2018 Meeting in
Oct 15, 2018

Summary Toggle aTyr Pharma Announces Leadership Transition

SAN DIEGO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the resignation of David J. King , Ph.D.
Sep 27, 2018

Summary Toggle aTyr Pharma Announces Pulmonary Sarcoidosis as Disease Indication for Phase 1b/2a Clinical Study and Educational Webinar

Conference Call and Webcast Featuring Leading Sarcoidosis Expert Dr. Daniel Culver on October 8, 2018 at 8:00 am ET SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on
Sep 20, 2018

Summary Toggle aTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

SAN DIEGO , Sept. 20, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., president and chief executive officer,
Aug 30, 2018

Summary Toggle aTyr Pharma to Present at the Baird 2018 Global Healthcare Conference

SAN DIEGO , Aug. 30, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., president and chief executive officer,
Aug 14, 2018

Summary Toggle aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update

Conference Call Today at 5:00 p.m. ET / 2:00 p.m. PT SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results